Projects

100 EXOMES

In Argentina, rare diseases affect around 3.2 million inhabitants. In this context, the analysis of the entire genome, and especially its coding part (the exome), has become a very useful tool in molecular diagnostics due to the variety of genes involved and / or the complexity of the clinical symptoms displayed by these patients. The 100 Exomes Project, in which Bitgenia worked together with specialists from the Faculty of Exact and Natural Sciences (University of Buenos Aires), summoned health professionals who had patients with high suspicion, based on the previous medical history, of rare monogenic diseases. The main aim of this project was to benefit patients that otherwise were unable to access and afford these technologies, giving them the opportunity to potentially arrive at a correct diagnosis.

PAMPA PROJECT 1.0

The Argentine Program of Precision Medicine in Autoinflammatory Diseases, better known as PAMPA Project, developed in the 2018 with the support of Novartis and the advice of an advisory board, composed of physicians and biochemists specialized in Rheumatology and Immunology. The project aimed to make a free accurate diagnosis of 60 patients with tentative diagnosis of Autoinflammatory Diseases (AID), using genomic technology and promoting appropriate treatment in the context of a true personalized medicine.

PAMPA PROJECT 2.0

The second version of the Argentine Program of Precision Medicine in Autoinflammatory Diseases, better known as PAMPA 2 Project, is taking place with the support of Novartis and the advice of an advisory board, composed of physicians and biochemists specialized in Rheumatology and Immunology. The project aimed to make free accurate diagnosis of 55 patients with tentative diagnosis of Autoinflammatory Diseases (AID), using genomic technology and promoting appropriate treatment in the context of a true personalized medicine.<

CONDOR PROJECT

The Colombian Program of Precision Medicine in Autoinflammatory Diseases, better known as Condor Project, is developed by Bitgenia with the support of Novartis of Colombia SA and the advice of an advisory board, composed of physicians specialized in Rheumatology. This project is taking place during 2020 and consists in analyzing the genomic data of 15 colombian patients with a tentative diagnosis of Autoinflammatory Diseases, using NGS techniques. The main aim of this project is to benefit patients unable to access and afford these technologies, giving them the opportunity to potentially arrive at a correct diagnosis while promoting an adequate treatment for a true personalized medicine.

Disclaimer, aviso de exención de responsabilidad y condiciones de uso

Bitgenia no proporciona consejo médico, diagnóstico o tratamiento. Los análisis e informes proporcionados por Bitgenia son únicamente con fines informativos y están sujetos a cambios. Los productos y servicios de Bitgenia son solo para su uso en la investigación y no se pueden usar en los procedimientos de diagnóstico. Por favor, tenga en cuenta que Bitgenia no ofrece ningún análisis genómico personal.

Design Estudio Demaro